Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Non-Inferiority Trial of Abaloparatide Transdermal System vs Subcutaneous Injection in Postmenopausal Osteoporosis
2019-004807-11Phase 3Completed
- Sponsor
- Radius Health Inc
- Start
- Mar 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abaloparatide in osteoporosis (2 arms), sponsored by Radius Health Inc. Primary endpoint: Percent change from baseline in lumbar spine BMD at 12 months. Started Mar 2020; status: completed.
02
Drugs
abaloparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2019-004807-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004807-11.